Estrella Immunopharma (ESLA) Net Cash Flow Growth (1y) (2022 - 2026)
Estrella Immunopharma (ESLA) Net Cash Flow Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 172.72% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 53.21% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 47.11% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 75.60% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -100.75% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2,045.25% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -104.22% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 149.49% |
| 10 | Estrella Immunopharma | 32.29 Mn | 32.14 Mn | - | -301.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -301.09% |
| Mar 31, 2026 | 209.22% |
| Dec 31, 2025 | 92.10% |
| Sep 30, 2025 | 104.28% |
| Jun 30, 2025 | 118.34% |
| Mar 31, 2025 | 88.53% |
| Dec 31, 2024 | -123.32% |
| Sep 30, 2024 | -136.87% |
| Jun 30, 2024 | -79,726.41% |
| Mar 31, 2024 | -247.48% |
| Dec 31, 2023 | 137.37% |
| Sep 30, 2023 | 1,886.80% |
| Jun 30, 2023 | 97.38% |
| Mar 31, 2023 | -690.92% |
| Dec 31, 2022 | -12,607.59% |
| Sep 30, 2022 | -244.55% |
| Jun 30, 2022 | -107.39% |
| Mar 31, 2022 | -473.47% |